Agios up as FDA gives Thermo Fisher glioma test breakthrough...

Shares in Agios Pharma ticked upwards after the FDA awarded breakthrough status to a companion diagnostic to vorasidenib, its experimental drug for brain cancer.

Tocagen plummets on phase 3 data for glioma therapy

Karyopharm drug tested in ‘industry-first’ approach to brain...

Bayer's regorafenib kicks off brain cancer platform trial

Bayer has become the first pharma company to take part in a new platform trial designed to find new treatments for brain cancer.

BMS’ Opdivo fails late-stage brain cancer test

Bristol-Myers Squibb has run into yet another hurdle trying to extend the use of its immuno-oncology blockbuster Opdivo into new types of cancer.

An echo through brain cancer’s empty pipeline

Brain tumours kill more people aged under 40 than any other cancer, yet there have been no new treatments for more than a decade. What’s more, there are still none in the pipeline.